SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLASs upcoming Phase 3 REGAL trial results for its GPS leukemia treatment dominate discussion, with topline data expected this month after the trial reached its final analysis milestone. Traders are split between optimism about a potential breakthrough and concern over the binary trial outcome, while sharp price swings have fueled debate about selling pressure and alleged short-term manipulation.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

Summits FDA review of ivonescimab for EGFR-mutated lung cancer is driving a binary-outcome debate over approval versus a possible rejection or request for more evidence. Bulls point to strong progression-free-survival results and encouraging survival trends, while bears focus on the FDAs stated need for statistically significant overall-survival evidence; recent weakness has also prompted speculation about a negative outcome, though traders say price action alone is not proof.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian shares are under pressure amid a broader pullback in EV and growth stocks, with traders also focused on the stocks persistent weakness and concerns about cash burn, profitability, and management. Some blame short sellers or trading dynamics, while bulls point to R2 progress and recent operating results as reasons for optimism; those explanations remain debated.

Unity Software, Inc. engages in the developing video gaming software. It also provides software solutions to create, run and monetize interactive, real-time two-dimensional and three-dimensional content for mobile phones, tablets, consoles, and augmented and virtual reality devices. Its platform is used by developers, artists, and designers to build content for gaming, film, retail, automotive, architecture, engineering, and construction industries. The company was founded by Joachim Ante and David Helgason in 2004 and is headquartered in San Francisco, CA.

Unity Software Inc

Unitys strong Q3 resultsits first GAAP-profitable quarter, rapid growth in its Vector ad platform, and upbeat outlookhave fueled a sharp rebound and discussion of a possible turnaround. Reported takeover talks with Silver Lake and Saudi Arabias PIF add speculation, with traders debating whether the discussed valuation would undervalue the company or whether a deal will happen at all.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

QQQs sharp after-hours drop drew attention as traders linked the move to the FAAs nationwide ground stop after communications problems, while speculation about a cyberattack or AI involvement remained unverified. The discussion also reflected wider pressure on tech and AI stocks tied to uncertainty around Nvidia, with traders divided between seeing the selloff as an overreaction and expecting further weakness.

American Airlines Group, Inc. is a holding company, which engages in the operation of a network carrier through its principal wholly owned mainline operating subsidiary, American. The firm offers air transportation for passengers and cargo. It operates through the following geographical segments: Domestic, Latin America, Atlantic, and Pacific. The company was founded on December 9, 2013, and is headquartered in Fort Worth, TX.

American Airlines Group Inc

Reports of an FAA nationwide ground stop tied to air-traffic-control communications problems are drawing attention to AAL, with traders discussing possible departure delays and rerouting. Some characterize the disruption as brief, while speculation about its cause remains unverified.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Jensen Huangs abrupt departure and the unresolved CEO succession are driving concern, with traders divided between those calling for his return and those worried about leadership continuity and scrutiny of Nvidias China-related chip sales. Upcoming earnings are another focus, but bullish bets on results and dip-buying compete with fears that uncertainty and further fallout could weigh on the stock.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius is selling off after lowering its revenue outlook amid delays activating third-party data-center capacity, prompting analyst concerns about execution and near-term growth; weakness across AI and neocloud stocks, alongside uncertainty around Nvidia, is adding pressure. Traders are split between viewing the delays and higher spending as serious risks and seeing them as temporary setbacks in a business with strong AI demand.

RUM Group, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

RUM Group Inc. - Ordinary Shares - Class A

RUM Group Inc.

RUMs strong third-quarter results and rapid growth in its Quake AI GPU-cloud business are driving attention as the companys AI-infrastructure pivot gains traction. Bulls point to improving operations and the Anthropic-linked expansion, while skeptics focus on losses, cash needs and financing risks; short-squeeze claims remain speculation.

HawKeye 360, Inc. engages in the provision of defense technology. It offers spectrum monitoring, maritime intelligence, air defence radar monitoring, GNSS interference detection, and communications mapping. Its costumers include a wide range of commercial, government and international entities. The company was founded by Charles T. Clancy, Robert G. McGwier, Chris DeMay and John Serafini in 2015 and is headquartered in Herndon, VA.

HawkEye 360 Inc.

HAWK is drawing attention after reporting record third-quarter revenue and raising its full-year outlook, with traders also highlighting international growth, contract demand, and plans for lower-cost satellites. The community reaction is broadly bullish on the results and rally, though claims of institutional accumulation and further upside remain speculative.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

AM Best Assigns Indicative Issue Credit Ratings to Elevance Health, Inc.s New Shelf Registration

AM Best has assigned indicative Long-Term Issue Credit Ratings of bbb+ (Good) to senior unsecured issues, bbb (Good) to subordinated issues and bbb- (Good) to preferred stock issues to the recently filed shelf registrations of Elevance Health, Inc. (Elevance Health) (Indianapolis, IN) [NYSE: ELV...

Can HUM's New Oncology Model Strengthen Its Value-Based Care Strategy?

Humana's new oncology model aims to speed cancer treatment, reduce administrative hurdles and advance its value-based care strategy through data analytics.

ELV or RVTY: Which Is the Better Value Stock Right Now?

ELV vs. RVTY: Which Stock Is the Better Value Option?

HUM Q3 Earnings Beat Estimates on Strong Insurance Performance

Humana's Q3 2026 loss is narrower than expected as Medicare membership and premiums grow, prompting a guidance hike despite rising benefit costs and expenses.

Can Higher Premiums Help Humana Beat Q3 Earnings Estimates?

HUM's Q3 premiums are expected to rise 26%, boosting its chances of an earnings beat even as higher operating costs and a worsening benefits expense ratio loom.

Is Astellas Pharma (ALPMY) Outperforming Other Medical Stocks This Year?

Here is how Astellas Pharma Inc. (ALPMY) and Elevance Health (ELV) have performed compared to their sector so far this year.

Will UNH's Optum Insight Spending Translate Into Profit Growth?

UnitedHealth is scaling AI solutions across Optum Insight to boost efficiency, improve claims processing and drive long-term growth despite rising costs.

Elevance Health (ELV) Is Up 2.73% in One Week: What You Should Know 

Does Elevance Health (ELV) have what it takes to be a top stock pick for momentum investors? Let's find out.

THC Q3 Earnings Beat on Hospital Strength, 2026 EPS View Raised

Tenet Healthcare's Q3 earnings surge 79.5% on strong hospital performance and cost discipline, prompting higher 2026 EPS and EBITDA guidance.

BSX Q3 Earnings Meet Estimates, Revenues Rise Y/Y, Stock Down

Boston Scientific's third-quarter revenues beat estimates, but contracting margins, weaker segment sales and reduced 2026 guidance weigh on shares.	

• Reported GAAP EPS of $6.99 up 15.92% YoY
• Reported revenue of $50.44B up 0.70% YoY
• Elevance Health raised FY 2026 diluted EPS guidance to at least $22.00, adjusted diluted EPS guidance to at least $29.00, and operating cash flow guidance to at least $6.5B.

Elevance Health medical membership decreased; adjusted operating expense ratio increased 90 basis points, while nine-month results included a $935M estimate of potential exposure tied to historical Medicare Advantage risk adjustment data.

Elevance Health reported Carelon revenue and operating gain increased, benefit expense ratio improved 70 basis points, and confidence in at least 12% adjusted diluted EPS growth in 2027.

Elevance Health, Inc. operates as a health company, which engages in improving lives and communities, and making healthcare simpler. It operates through the following segments: Health Benefits, CarelonRx, Carelon Services, and Corporate and Other. The Health Benefits segment offers a comprehensive suite of health plans and services to different customers. The CarelonRx segment markets and offers pharmacy services to affiliated health plan customers, as well as to external customers. The Carelon Services segment integrates physical, behavioral, pharmacy, and social services with the aim of delivering whole health affordably by offering a broad array of healthcare related services. The Corporate & Other segment includes businesses that do not individually meet the quantitative threshold for an operating segment. The company was founded in 1944 and is headquartered in Indianapolis, IN.

Elevance Health Inc

UNH Stock Rises Overnight Ahead Of Earnings: Analyst Outlines ‘Short Premium’ Play To Cut January Call Cost By Nearly 60%

Equity

Bearish Sentiment

<ul class="summary-bullets"><li>Khouw’s trade sells November $420 calls and $340 puts to help fund a January 2027 $400 call, lowering its cost by nearly 58%.</li><li>UnitedHealth is expected to post $112.4 billion in Q3 revenue, $6.45 billion in EBITDA and $3.06 in earnings per share.</li><li>Oppenheimer noted that UNH's share of members in four-star-or-higher plans fell 15%, while Humana’s rose to 95% from 42%.</li></ul><p>UnitedHealth (UNH) is set to report third-quarter (Q3) earnings before Tuesday’s market open, with options pricing in a 6.5% move around the results. Tidal Financial Group strategist Michael Khouw says elevated options prices create an opportunity for traders to sell November premium to help finance a cheaper January call.</p><p><a href="https://stocktwits.com/symbol/UNH">UNH stock</a> rose 0.9% in after-hours trading on Monday after closing the regular session down 0.2% at $378.52.</p><h2 class="st-heading-2"><strong>UnitedHealth Options Price In A 6.5% Earnings Move</strong></h2><p>“The only thing more expensive than health insurance is perhaps the costs of insuring shares of health insurers,” Khouw said, pointing to UnitedHealth as an example.</p><p>Options imply a 6.5% move in UnitedHealth shares around earnings, while implied volatility is running at about 40%, about twice the stock’s realized volatility of 20%, he said. The implied move is the second-largest in almost two years. Shares have fallen after five of their past eight earnings reports, including nearly 20% drops after results in January and April 2025, CNBC&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.cnbc.com/2026/10/12/unitedhealth-shares-are-doing-something-unusual-ahead-of-earnings.html?taid=6acd105f558573000116c2d1&amp;utm_campaign=trueanthem&amp;utm_content=main&amp;utm_medium=social&amp;utm_source=twitter">noted</a>.</p><h2 class="st-heading-2"><strong>UNH Call Play: How The $400 January Call Trade Cuts Upfront Cost By 58%</strong></h2><p>Khouw’s proposed trade is a “short premium” strategy: It sells two November options to collect $10.60 per share and offset part of the cost of a longer-dated call.&nbsp;</p><div><figure class="table"><table class="ck-table-resized"><colgroup><col><col><col></colgroup><tbody><tr><td>Leg&nbsp;</td><td>Trade&nbsp;</td><td>Premium Per Share&nbsp;</td></tr><tr><td>1</td><td>Buy January 2027 $400 Call</td><td>Pay $18.20</td></tr><tr><td>2</td><td>Sell November $420 Call&nbsp;</td><td>Collect $5.80</td></tr><tr><td>3</td><td>Sell November $340 Put</td><td>Collect $4.80</td></tr><tr><td>&nbsp;</td><td>Net Upfront Debit</td><td>$7.60</td></tr></tbody></table></figure></div><p>The trade buys a January 2027 $400 call for $18.20 per share, then sells a November $420 call for $5.80 and a November $340 put for $4.80. The resulting net cost is $7.60 per share, or $760 per contract, reducing the call’s upfront cost by about 58%.&nbsp;</p><h2 class="st-heading-2"><strong>What Could Go Wrong If UNH Moves Sharply?</strong></h2><p>If UnitedHealth finishes November between $340 and $420: The short options would expire worthless. The January call’s breakeven would be $407.60 at expiration.</p><p>If UNH stock falls below $340: The short put could require the seller to buy shares at that price, for an effective cost of about $347.60 per share after the trade’s net debit.</p><p>Khouw said UnitedHealth had been essentially flat over five years and traded 12% to 13% below the midpoint of its two-year high-low range. At about 17 times forward earnings, he said, the stock was not priced for a recovery. He sees the company’s 13% to 16% earnings-growth target as achievable, though rising healthcare costs is a headwind.</p><p>Khouw also pointed to enrollment trends. Affordable Care Act (ACA) marketplace enrollment appears poised to decline, he said, although the segment is smaller than Medicare and commercial coverage. Commercial fee-based enrollment grew about 2.9% from 2024 to 2025, while total Medicare enrollment rose 4.5%. Commercial growth exceeded U.S. workforce growth of about 1.4%.</p><h2 class="st-heading-2"><strong>UNH Q3 Earnings Preview</strong></h2><p>Koyfin’s estimates for the upcoming quarter compare with the last reported quarter. They show revenue of $111.49 billion, down 0.5% sequentially. Earnings before interest, taxes, depreciation and amortization (EBITDA) is estimated at $6.47 billion, down 28%, while earnings before interest and taxes (EBIT) is forecast at $5.44 billion, down 32%. GAAP earnings per share (EPS) are projected to fall 36.81%.</p><p>Fiscal.ai’s year-over-year estimates show revenue of $112.4 billion, compared with $113.2 billion a year earlier. It forecasts EBITDA of $6.45 billion, up from $5.25 billion, and earnings per share of $3.06, compared with $2.92.</p><h2 class="st-heading-2"><strong>Medicare Advantage Ratings: Wall Street Weighs UNH Against Peers</strong></h2><p>TD Cowen lowered its price target on UNH to $402 from $430, implying a 6% upside, while maintaining a 'Buy' rating. The firm expects preliminary commentary on 2027 earnings-per-share expectations with the report.&nbsp;</p><p>Meanwhile, Piper Sandler said 66.8% of UnitedHealth members were enrolled in plans rated four stars or higher, based on September 2026 enrollment data, and called the company’s resilience “impressive” and underappreciated. Oppenheimer noted that the share of members in four-star-or-higher plans fell 15% at UnitedHealth for 2027, versus 10% at Elevance Health, 15% at CVS Health and 9% at Centene. Humana moved in the opposite direction, with 95% of its members in four-star-or-higher plans, up from 42% a year earlier.&nbsp;</p><h2 class="st-heading-2"><strong>How Do Retail Traders Feel About UNH?</strong></h2><p>On Stocktwits, retail sentiment for UNH jumped to ‘extremely bullish’ from ‘bullish’ levels a day ago amid a 1,680% surge in 24-hour message volumes.</p><figure class="image"><img src="https://news.stocktwits-cdn.com/unh_ss_d30ab9f499.png" alt="unh ss.png" width="633" height="342"><figcaption>UNH sentiment and message volume as of October 13 | Source: Stocktwits</figcaption></figure><p>One user&nbsp;<a href="https://stocktwits.com/Jimsonlima/message/666329330">said</a>, “$UNH beat and raise. 500 incoming”</p><p><stembedurl>https://stocktwits.com/Jimsonlima/message/666329330</stembedurl></p><p>Another user&nbsp;<a href="https://stocktwits.com/Bobky2030/message/666326375">said</a>, “$UNH be cool to beat huge and raise. Shorts have to chase to 435.00 plus this week.”</p><p><stembedurl>https://stocktwits.com/Bobky2030/message/666326375</stembedurl></p><p>UNH stock has risen 17% year-to-date.</p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p><p>Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/michael-burry-bull-trap-risk-holds-back-new-shorts-trump-fannie-freddie-call/cZxBdKIRBob">‘The Trick Is To Get There’: Michael Burry Sees ‘Bull Trap’ Risk But Holds Back On New Shorts&nbsp;</a></p>

In this photo illustration, the UnitedHealth Group logo is displayed on the screen of a smartphone. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Tidal Financial Group strategist Michael Khouw says options imply a 6.5% earnings move, with implied volatility at 40%, twice the stock’s realized volatility.

Centene Corp.

CVS Health Corp

Humana Inc

Unitedhealth Group Inc

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '26	$2.08	--	--	N/A
Q3 '26	$4.71	$6.99	48.28%	BEAT
Q2 '26	$6.21	$7.45	19.94%	BEAT
Q1 '26	$11.03	$12.58	14.02%	BEAT
Q4 '25	$3.10	$3.33	7.54%	BEAT

Feed

News

Sentiment

Earnings

Fundamentals

Info

ELV Earnings

Latest Earnings Results: Q3 '26

Historical Earnings